Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Hematology

• Publication date

  2018-08-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-018-3480-9PMID 30159599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring of post‐transplant CBFB‐MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia

  2018cited by this paper
• Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation

  2018cited by this paper
• The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission

  2017cited by this paper
• Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

  2017cited by this paper
• Effects of pre‐ and post‐transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen‐matched or mismatched related donor allografts

  2017cited by this paper
• SNX2–ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis

  2017cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

  2016cited by this paper
• Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.

  2016cited by this paper
• Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

  2015cited by this paper
• Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy

  2015cited by this paper
• Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

  2014cited by this paper
• Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML

  2014cited by this paper
• Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

  2013cited by this paper
• Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

  2013cited by this paper
• Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

  2012cited by this paper
• Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

  2012cited by this paper
• Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.

  2011cited by this paper
• Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

  2010cited by this paper
• Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children.

  2009cited by this paper
• Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.

  2009cited by this paper
• Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.

  2009cited by this paper
• Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

  2006cited by this paper
• Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies

  2006cited by this paper
• Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

  2005cited by this paper
• Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

  2004cited by this paper
• Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

  2003cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

  1998cited by this paper

• [Prognostic significance of molecular minimal residual disease before and after allogeneic hematopoietic stem cell transplantation in children with acute myeloid leukemia].

  2025cites this paper
• Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

  2023cites this paper
• MRD-directed and risk-adapted individualized stratified treatment of AML.

  2023cites this paper
• Biological and molecular markers in childhood malignancies

  2021cites this paper
• How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring

  2021cites this paper
• Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

  2021cites this paper
• Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective

  2021cites this paper
• Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes

  2021cites this paper
• Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia

  2021cites this paper
• Precision medicine in myeloid malignancies.

  2021cites this paper
• Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11

  2021cites this paper
• Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia

  2020cites this paper